why choose us

300×250 Ad Slot

Research Article: Biosimilars Would Reduce Health Care Costs But Are Yet Poorly Known – Patient Survey Study Among Biological Medicine Users

Date Published: 2024-02-03

Abstract:
Biological medicines are a rapidly growing type of therapy available to treat for example cancers and immune-mediated inflammatory conditions such as rheumatic diseases, inflammatory bowel diseases (IBD), and psoriasis. Adalimumab and etanercept were among the most reimbursement costs causing biological medicines in Finland in . Introduction of biosimilars has resulted in considerable cost savings in public funded health care regimes in many countries., Biosimilars are in structure and function similar to originator biological medicines and can therefore be extrapolated for use in same indications. In , experts representing medicines agencies from four European countries have concluded that switching between comparable biological substances approved in the European Union (EU) is not expected to trigger or enhance immunogenicity, which has been the main concern in discussion about changes between different biological medicines. Biosimilars are expected to increase patients' access to in every case high cost biological medicines, and gradually, more patients will be switched to biosimilars either by doctors’ prescriptions or mandatory national indications. Economic impact of these switches is expected to be remarkable in the coming years.

Introduction:
Biological medicines are a rapidly growing type of therapy available to treat for example cancers and immune-mediated inflammatory conditions such as rheumatic diseases, inflammatory bowel diseases (IBD), and psoriasis. Adalimumab and etanercept were among the most reimbursement costs causing biological medicines in Finland in . Introduction of biosimilars has resulted in considerable cost savings in public funded health care regimes in many countries. , Biosimilars are in structure and function similar to…

Read more

300×250 Ad Slot